Brainstem Raphe Echogenicity and Insomnia in Type 2 Diabetes: An Exploratory Cross-Sectional Study

Area of Science:

• Neuroscience
• Endocrinology
• Psychiatry

Background:

• Type 2 diabetes mellitus (T2DM) is linked to increased depression risk, possibly due to brainstem raphe nuclei alterations.
• Raphe hypoechogenicity, detectable via transcranial sonography (TCS), is explored as a potential neurobiological marker in T2DM.
• Investigating the link between raphe echogenicity and mental health symptoms in T2DM is crucial for understanding disease comorbidities.

Purpose of the Study:

• To determine if raphe hypoechogenicity in T2DM patients is associated with depressive, anxiety, and sleep symptoms.
• To examine the relationship between raphe alterations and diabetes-related complications.
• To assess the robustness of these associations using statistical adjustments and subgroup analyses.

Main Methods:

• A cross-sectional study involving 230 T2DM patients and non-diabetic controls.
• Transcranial sonography (TCS) used to assess raphe echogenicity.
• Mental health assessed using Patient Health Questionnaire 9 (PHQ-9) and Emotional Well-Being Questionnaire (EWQ); propensity score adjustment used.

Main Results:

• Raphe hypoechogenicity showed a preliminary association with higher insomnia scores (EWQ6), but this was not significant after adjusting for sleep medication and multiple comparisons.
• No significant associations were found between raphe echogenicity and depressive (PHQ-9) or other anxiety/well-being symptoms (EWQ subscales).
• Individuals with hypoechogenic raphe had a higher prevalence of diabetes-related complications (32% vs. 7%).

Conclusions:

• Reduced raphe echogenicity in T2DM was not robustly linked to overall depression or anxiety severity in this exploratory study.
• A potential association with sleep-related symptoms was observed but lacked statistical robustness.
• Findings suggest raphe hypoechogenicity may be linked to complications and warrants further investigation in larger, longitudinal, and medication-naïve cohorts.